Stocks
Galera Therapeutics IncGRTX
PNKHealthcareBiotechnology$16.28
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing dismutase mimetics to treat radiation-induced toxicities in cancer patients. Its lead candidate, avasopasem manganese, has completed Phase 3 trials for oral mucositis with mixed results, and the company is now evaluating strategic alternatives after a difficult capital market environment. Investors track GRTX for its remaining cash runway and potential approval or partnership outcomes.
52W Range: $0.09-$30.00
Congressional Interest in Galera Therapeutics Inc (GRTX)
No congressional trades have been disclosed for Galera Therapeutics Inc (GRTX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading GRTX?
No congressional trades found for this stock.